Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004% ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost

Criteria

Inclusion Criteria:

• Diagnosis of normal tension glaucoma.

• Must sign an Informed Consent form.

• IOP within protocol-specified range.

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Pregnant and lactating women, or women who intend to become pregnant during the study period.

• Advanced and serious glaucoma, as specified in protocol.

• Complicated chronic or recurrent uveitis, scleritis or corneal herpes.

• History of ocular trauma, intraocular surgery or laser surgery for the included eye.

• Ocular-infection and severe ocular complication.

• Best-corrected visual acuity (BCVA) worse than 0.2 decimal.

• Difficulty in conducting applanation tonometry for the included eye as determined by the doctor.

• Severe or serious hypersensitivity to prostaglandin analogues or any ingredients used in the study.

• Use of IOP lowering ophthalmic solutions other than TRAVATAN Z® or oral carbonic anhydrase inhibitor (Diamox, etc.) during the study period.

• Use of any adrenocorticosteroids during the study period.

• Use of IOP lowering ophthalmic solution within the past 30 days.

• Regarded by doctor as not suitable for study participation.

• Other protocol-specified exclusion criteria may apply.